Antibody therapies for the prevention and treatment of viral infections

Abstract Antibodies are an important component in host immune responses to viral pathogens. Because of their unique maturation process, antibodies can evolve to be highly specific to viral antigens. Physicians and researchers have been relying on such high specificity in their quest to understand ho...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Georgina Salazar, Ningyan Zhang, Tong-Ming Fu, Zhiqiang An
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/343a3307f4014107baf26bf2a734ba97
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:343a3307f4014107baf26bf2a734ba97
record_format	dspace
spelling	oai:doaj.org-article:343a3307f4014107baf26bf2a734ba972021-12-02T16:06:13ZAntibody therapies for the prevention and treatment of viral infections10.1038/s41541-017-0019-32059-0105https://doaj.org/article/343a3307f4014107baf26bf2a734ba972017-07-01T00:00:00Zhttps://doi.org/10.1038/s41541-017-0019-3https://doaj.org/toc/2059-0105Abstract Antibodies are an important component in host immune responses to viral pathogens. Because of their unique maturation process, antibodies can evolve to be highly specific to viral antigens. Physicians and researchers have been relying on such high specificity in their quest to understand host–viral interaction and viral pathogenesis mechanisms and to find potential cures for viral infection and disease. With more than 60 recombinant monoclonal antibodies developed for human use in the last 20 years, monoclonal antibodies are now considered a viable therapeutic modality for infectious disease targets, including newly emerging viral pathogens such as Ebola representing heightened public health concerns, as well as pathogens that have long been known, such as human cytomegalovirus. Here, we summarize some recent advances in identification and characterization of monoclonal antibodies suitable as drug candidates for clinical evaluation, and review some promising candidates in the development pipeline.Georgina SalazarNingyan ZhangTong-Ming FuZhiqiang AnNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 2, Iss 1, Pp 1-12 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Georgina Salazar Ningyan Zhang Tong-Ming Fu Zhiqiang An Antibody therapies for the prevention and treatment of viral infections
description	Abstract Antibodies are an important component in host immune responses to viral pathogens. Because of their unique maturation process, antibodies can evolve to be highly specific to viral antigens. Physicians and researchers have been relying on such high specificity in their quest to understand host–viral interaction and viral pathogenesis mechanisms and to find potential cures for viral infection and disease. With more than 60 recombinant monoclonal antibodies developed for human use in the last 20 years, monoclonal antibodies are now considered a viable therapeutic modality for infectious disease targets, including newly emerging viral pathogens such as Ebola representing heightened public health concerns, as well as pathogens that have long been known, such as human cytomegalovirus. Here, we summarize some recent advances in identification and characterization of monoclonal antibodies suitable as drug candidates for clinical evaluation, and review some promising candidates in the development pipeline.
format	article
author	Georgina Salazar Ningyan Zhang Tong-Ming Fu Zhiqiang An
author_facet	Georgina Salazar Ningyan Zhang Tong-Ming Fu Zhiqiang An
author_sort	Georgina Salazar
title	Antibody therapies for the prevention and treatment of viral infections
title_short	Antibody therapies for the prevention and treatment of viral infections
title_full	Antibody therapies for the prevention and treatment of viral infections
title_fullStr	Antibody therapies for the prevention and treatment of viral infections
title_full_unstemmed	Antibody therapies for the prevention and treatment of viral infections
title_sort	antibody therapies for the prevention and treatment of viral infections
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/343a3307f4014107baf26bf2a734ba97
work_keys_str_mv	AT georginasalazar antibodytherapiesforthepreventionandtreatmentofviralinfections AT ningyanzhang antibodytherapiesforthepreventionandtreatmentofviralinfections AT tongmingfu antibodytherapiesforthepreventionandtreatmentofviralinfections AT zhiqiangan antibodytherapiesforthepreventionandtreatmentofviralinfections
_version_	1718385079517970432

Antibody therapies for the prevention and treatment of viral infections

Ejemplares similares